242 related articles for article (PubMed ID: 33078727)
1. A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with
Mokhtare M; Nikkhah M; Behnam B; Agah S; Bahardoust M; Masoodi M; Faghihi A
Indian J Pharmacol; 2020; 52(4):266-271. PubMed ID: 33078727
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
Chuah SK; Liang CM; Lee CH; Chiou SS; Chiu YC; Hu ML; Wu KL; Lu LS; Chou YP; Chang KC; Kuo CH; Kuo CM; Hu TH; Tai WC
Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
[TBL] [Abstract][Full Text] [Related]
3. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
7. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
8. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial.
Kamal A; Ghazy RM; Sherief D; Ismail A; Ellakany WI
BMC Infect Dis; 2023 Jan; 23(1):36. PubMed ID: 36670359
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Lee H; Hong SN; Min BH; Lee JH; Rhee PL; Lee YC; Kim JJ
Dig Liver Dis; 2015 Feb; 47(2):114-8. PubMed ID: 25467826
[TBL] [Abstract][Full Text] [Related]
12. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
De Francesco V; Pontone S; Bellesia A; Serviddio G; Panetta C; Palma R; Zullo A
Dig Liver Dis; 2018 Feb; 50(2):139-141. PubMed ID: 29089267
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
Federico A; Nardone G; Gravina AG; Iovene MR; Miranda A; Compare D; Pilloni PA; Rocco A; Ricciardiello L; Marmo R; Loguercio C; Romano M
Gastroenterology; 2012 Jul; 143(1):55-61.e1; quize e13-4. PubMed ID: 22484118
[TBL] [Abstract][Full Text] [Related]
14. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection.
Alsohaibani F; Al Ashgar H; Al Kahtani K; Kagevi I; Peedikayil M; Alfadda A; Khan M
Saudi J Gastroenterol; 2015; 21(4):220-5. PubMed ID: 26228365
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
Su J; Zhou X; Chen H; Hao B; Zhang W; Zhang G
Medicine (Baltimore); 2017 Feb; 96(7):e5859. PubMed ID: 28207505
[TBL] [Abstract][Full Text] [Related]
16. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
[TBL] [Abstract][Full Text] [Related]
17. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
[TBL] [Abstract][Full Text] [Related]
18. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
19. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
Liou JM; Chen CC; Chen MJ; Chang CY; Fang YJ; Lee JY; Sheng WH; Wang HP; Wu MS; Lin JT
J Antimicrob Chemother; 2011 Aug; 66(8):1847-52. PubMed ID: 21632579
[TBL] [Abstract][Full Text] [Related]
20. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Zullo A; Scaccianoce G; De Francesco V; Ruggiero V; D'Ambrosio P; Castorani L; Bonfrate L; Vannella L; Hassan C; Portincasa P
Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):647-50. PubMed ID: 23747131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
